Who is sponsoring NCT00866203?

NCT00866203 is sponsored by Gruppo Italiano Studio Linfomi.

What condition does NCT00866203 study?

NCT00866203 studies High-Grade Lymphomas.

What drugs are being tested in NCT00866203?

Interventions: HDS vs ProMECE/CytaBOM.

What is the status of NCT00866203?

NCT00866203 is currently COMPLETED.

Last reviewed 2009-03-19 · How we verify

A Prospective, Randomized, Multicenter Trial Comparing a Modified HDS Therapy Supported by PBPC Transplant With Additional 4 Courses of Front-Line Therapy in Adult Aggressive NHL With PR After Short Course of Up-Front Chemotherapy

NCT00866203 Phase 3 COMPLETED

The study is planned to compare the outcome of aggressive NHL patients in partial remission after four courses of front-line therapy, randomly assigned to receive either additional four courses of the same regimen or a modified HDS program.

Details

Lead sponsor	Gruppo Italiano Studio Linfomi
Phase	Phase 3
Status	COMPLETED
Enrolment	441
Start date	2000-10
Completion	2008-04

Conditions

High-Grade Lymphomas

Interventions

HDS vs ProMECE/CytaBOM

Primary outcomes

remission duration — end of treatment
overall survival — study end
event-free survival — study end
freedom-from progression — study end

Countries

Italy